Post COVID‐19 vaccination: AusVaxSafety survey participation and adverse events – a community‐based regional Queensland study. (3rd October 2022)
- Record Type:
- Journal Article
- Title:
- Post COVID‐19 vaccination: AusVaxSafety survey participation and adverse events – a community‐based regional Queensland study. (3rd October 2022)
- Main Title:
- Post COVID‐19 vaccination: AusVaxSafety survey participation and adverse events – a community‐based regional Queensland study
- Authors:
- Hamilton, Elizabeth
Oversby, Shannen
Kitchener, Scott
Ratsch, Angela - Abstract:
- Abstract: Objective : To describe adverse events following COVID‐19 immunisation (AEFI) and participation in AusVaxSafety surveillance in a Queensland regional community. Methods : Participants presenting for second dose COVID‐19 vaccine at the Hervey Bay Wide Bay Hospital and Health Service (WBHHS) vaccine clinic in July 2021 completed a survey pertaining to their first COVID‐19 vaccine. Data collected included participation in AusVaxSafety surveillance, vaccine type (BNT162b2 (Pfizer/BioNTech) or ChAdOx1‐S(Oxford/AstraZeneca), AEFI experienced and impact on work/routine activities. Multivariable logistic regression related demographic factors to odds of surveillance participation and AEFI occurrence. Results : Of 1, 148 participants, 37.6% participated in AusVaxSafety surveillance and 44.8% reported an AEFI. Participation in surveillance was higher in older (≥50 vs <50 years: OR 1.36, 95%CI:1.04–1.78) and less‐educated participants (university vs. high school/below: OR 0.68, 95%CI:0.48–0.95). Reporting an AEFI was higher in younger (≥50 years vs. <50 years: BNT162b2: OR 0.69, 95%CI:0.51–0.93; ChAdOx1‐S: OR 0.42, 95%CI:0.10–1.89), female (female vs. male: BNT162b2: OR 2.28, 95%CI:1.67–3.12; ChAdOx1‐S: OR 1.85, 95%CI:1.17–2.94) and more educated participants (university vs. high school/below: BNT162b2:OR 1.63, 95%CI: 1.08–2.45; ChAdOx1‐S: OR 3.98, 95%CI:2.03–7.79). Of participants with an AEFI, 15% reported missing work/routine activities. Conclusions : Participation inAbstract: Objective : To describe adverse events following COVID‐19 immunisation (AEFI) and participation in AusVaxSafety surveillance in a Queensland regional community. Methods : Participants presenting for second dose COVID‐19 vaccine at the Hervey Bay Wide Bay Hospital and Health Service (WBHHS) vaccine clinic in July 2021 completed a survey pertaining to their first COVID‐19 vaccine. Data collected included participation in AusVaxSafety surveillance, vaccine type (BNT162b2 (Pfizer/BioNTech) or ChAdOx1‐S(Oxford/AstraZeneca), AEFI experienced and impact on work/routine activities. Multivariable logistic regression related demographic factors to odds of surveillance participation and AEFI occurrence. Results : Of 1, 148 participants, 37.6% participated in AusVaxSafety surveillance and 44.8% reported an AEFI. Participation in surveillance was higher in older (≥50 vs <50 years: OR 1.36, 95%CI:1.04–1.78) and less‐educated participants (university vs. high school/below: OR 0.68, 95%CI:0.48–0.95). Reporting an AEFI was higher in younger (≥50 years vs. <50 years: BNT162b2: OR 0.69, 95%CI:0.51–0.93; ChAdOx1‐S: OR 0.42, 95%CI:0.10–1.89), female (female vs. male: BNT162b2: OR 2.28, 95%CI:1.67–3.12; ChAdOx1‐S: OR 1.85, 95%CI:1.17–2.94) and more educated participants (university vs. high school/below: BNT162b2:OR 1.63, 95%CI: 1.08–2.45; ChAdOx1‐S: OR 3.98, 95%CI:2.03–7.79). Of participants with an AEFI, 15% reported missing work/routine activities. Conclusions : Participation in surveillance was modest in this regional population, despite AEFI being frequent, and impacts of absenteeism in this setting warrants further research. Implications for public health : The findings can inform strategies to improve surveillance participation and inform workforce planning in regional areas. … (more)
- Is Part Of:
- Australian and New Zealand journal of public health. Volume 46:Number 6(2022)
- Journal:
- Australian and New Zealand journal of public health
- Issue:
- Volume 46:Number 6(2022)
- Issue Display:
- Volume 46, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 46
- Issue:
- 6
- Issue Sort Value:
- 2022-0046-0006-0000
- Page Start:
- 738
- Page End:
- 744
- Publication Date:
- 2022-10-03
- Subjects:
- COVID‐19 -- vaccine surveillance -- regional health -- adverse event following immunisation
Public health -- Australia -- Periodicals
Public health -- New Zealand -- Periodicals
Medical care -- Australia -- Periodicals
Medical care -- New Zealand -- Periodicals
362.10993 - Journal URLs:
- https://www.sciencedirect.com/journal/australian-and-new-zealand-journal-of-public-health ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1753-6405 ↗
http://www.blackwell-synergy.com/loi/azph ↗
http://www.blackwellpublishing.com/journal.asp?ref=1326-0200&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1753-6405.13300 ↗
- Languages:
- English
- ISSNs:
- 1326-0200
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1796.894000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24614.xml